Ondansetron
Jump to navigation
Jump to search
![]() | |
---|---|
![]() | |
Systematic (IUPAC) name | |
(RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4(9H)-one | |
Identifiers | |
CAS number | 99614-02-5[CAS] |
ATC code | A04AA01 |
PubChem | CID 4595 |
IUPHAR ligand | 2290 |
DrugBank | DB00904 |
ChemSpider | 4434 ![]() |
UNII | 4AF302ESOS ![]() |
KEGG | D00456 ![]() |
ChEMBL | CHEMBL46 ![]() |
Chemical data | |
Formula | |
Mol. mass | 293.4 g/mol |
SMILES | eMolecules & PubChem |
| |
Pharmacokinetic data | |
Bioavailability | ~60% |
Protein binding | 70%-76% |
Metabolism | Hepatic (CYP3A4, CYP1A2, CYP2D6) |
Half-life | 5.7 hours |
Excretion | Renal |
Therapeutic considerations | |
Pregnancy cat. | B1(AU) B(US) |
Legal status | Prescription Only (S4) (AU) ℞ -only (CA) POM (UK) ℞ -only (US) |
Routes | Oral, rectal, IV, IM |
![]() |
Ondansetron është emri i një ilaçi që përdoret kryesisht si antiemetik (për trajtimin e të vjellave). Ilaçi vepron në sistemin nervor qëndror dhe periferik, duke shërbyer si anatagonist i receptorëve 5-HT3 të serotoninës.